Leon Kircik, MD, a board-certified dermatologist at the Icahn School of Medicine at Mount Sinai in New York, New York, discusses the history of isotretinoin and emerging treatments such as Absorica LD. He describes the adverse event profile of isotretinoin with increased triglycerides. He reviews the fewer dietary restrictions in Absorica LD compared to traditional isotretinoin, allowing patients to avoid the requirement of consuming a high-fat meal for absorption. Absorica LD has also shown the ability to improve bioavailability through micronization and lipid encapsulation, reducing particle size and enhancing solubility and dissolution. An improved bioavailability with this treatment has led patients with acne to have higher plasma levels and lower dosing requirements, making it more effective and convenient for patients.
